HIV persists despite antiretroviral therapy (ART) in cellular reservoirs thought to occur in distinct anatomical compartments. Therapy failure may occur because of incomplete ART adherence and possibly viral replication at some reservoir sites. The CNS may serve as a reservoir site due to lowered ART penetration and virus production from long-lived tissue resident macrophages. Compelling evidence for the CNS as a reservoir is the existence of individuals where HIV is suppressed below limit of detection in blood but detectable in the cerebrospinal fluid (CSF), termed CSF Escape. Here, we asked whether HIV in CSF Escape individuals is derived from macrophages or persists due to lowered ART. We used cell surface markers on the HIV envelope to determine the cellular source of HIV. We verified detection using in vitro derived virus from infected macrophages and T cells and tested CSF from CSF Escape individuals. We observed host surface markers consistent with T cell origin. We also measured ART concentrations in the CSF and plasma. We found a dramatic decrease in CSF ART concentrations described previously, but no significant difference between CSF Escape versus fully suppressed individuals. To examine the effect of the observed CSF ART concentrations on HIV replication, we used long-term infection with ART in cell culture. CSF Escape ART levels led to either HIV suppression or evolution of drug resistance, but not replication of drug sensitive HIV. These observations argue that persistent CNS viremia despite ART can be T cell generated and may result in drug resistance and therapy failure.
Introduction

1
HIV persistence in the face of ART necessitates lifelong adherence to treatment. The 2 CNS may serve as one reservoir for HIV persistence [3, 41] . HIV infection in the CNS in 3 the absence of suppressive ART may lead to HIV-associated neurocognitive disorders 4 (HAND). Yet, even in the presence of ART mediated suppression, there is evidence that 5 sub-clinical cognitive impairment is common [9, 16, 18, 27, 34, 39, 40, 43, 59-61, 66-68, 75] . 6 Another observation which supports HIV mediated effects in the face of ART in the 7 CNS is widespread immune activation and inflammation in this compartment in the 8 presence of therapy [1, 19, 36, 44, 79] . 9 The elimination of the HIV reservoir in the brain may improve the quality of life of 10 infected individuals. It may also be part of a strategy to cure HIV infection by targeting 11 HIV reservoirs, which may be necessary across all compartments where such reservoirs 12 persist [15, 20] . One line of evidence that the brain harbours appreciable virus in the 13 face of ART comes from individuals who have detectable viremia in the CSF, where the 14 CSF is used as a proxy for HIV infection in the CNS [11, 23, 49, 55] , while being 15 successfully suppressed below the level of detection in the blood. 16 In most cases, long-term adherence to ART does not lead to the evolution of drug 17 resistant virus [15, 20] . One mechanism consistent with long-term persistence of ART 18 sensitive HIV is a reservoir of latently infected CD4+ resting T cells [13-15, 20, 28, 64] . 19 This reservoir is expected to be replenished by cellular homeostatic proliferation [12] , 20 not viral replication with the associated evolution of drug resistance [52] . This type of 21 persistence mechanism may also involve other long-lived cell types. Examples include 22 macrophage-linage cells such as microglia and perivascular macrophages [3, 35, 60, 61, 78] 23 in the CNS. Tissue resident macrophages may persist for years [33, 56] , and the 24 cytotoxic effects of HIV infection on macrophages are observed to be low [4] . This 25 would enable such infected cells to contribute to the HIV virus pool without requiring 26 reinfection in the presence of ART. Also, cell-to-cell HIV spread originating from 27 macrophages has been reported to have decreased ART sensitivity [22] . 28 In addition to long-lived infected macrophage lineage cells, another reason the CNS 29 may serve as a reservoir for HIV in the face of ART is the low drug penetration into this 30 compartment. Reported fold-decrease in ART levels for the common reverse 31 transcriptase inhibitor based regimen of efavirenz (EFV), emtricitabine (FTC), and and 32 tenofovir (TFV) are approximately 200-fold, 2-fold, and 20-fold, respectively [5, 7, 8, 25] . 33 Sufficiently decreased ARV concentrations may allow ongoing replication to occur. 34 Whether HIV replication would lead to evolution of drug resistance would depend on 35 sufficient selective pressure to favour drug resistant over drug sensitive virus [58] . A 36 report describing evolution in the lymph node compartment in the face of ART [50] 37 postulated that at sufficiently decreased drug concentrations [30] , an anatomical site 38 can serve as a sanctuary for drug sensitive virus, which allows such virus to replicate 39 but not evolve drug resistance because ART levels are too low. Drug sensitive virus 40 would therefore be unable to escape the sanctuary site until ART is interrupted. Such a 41 scenario would be an explanation for the lack of evolution of drug resistance with HIV 42 replication in the face of ART.
43
Here we aimed to determine if viremia detected in the CSF of CSF Escape individuals 44 was of macrophage origin, or able to replicate as drug sensitive virus in the CNS due to 45 lowered ART concentrations. We interrogated the CSF and matched peripheral blood of 46 HIV infected individuals on a regimen of EFV, FTC, and TFV. We determined the cellular source of HIV by taking advantage of the fact that upon budding, HIV retains 48 the plasma membrane of the host cell as its envelope. This contains host surface 49 markers which may be used to detect the cellular source of the virus [46-48, 51, 74] . Our 50 results were consistent with a T cell source of HIV in CSF Escape. 51 We also measured ART concentrations in the plasma and CSF using liquid 52 chromatography-tandem mass spectrometry (LC-MS/MS) and performed evolution at 53 the measured drug concentrations to determine if drug sensitive virus could persist. The 54 decline in viral replication at the measured drug concentrations for individuals with 55 CSF Escape led to a disappearance of infected cells in vitro over time, indicating that 56 despite the precipitous drop in drug levels, they are nevertheless sufficiently potent to 57 suppress HIV. Introducing an adherence gap and sequential transfer of virus from lower 58 to higher concentrations led to the evolution of high level drug resistance. Hence, we 59 conclude that the CNS is not a sanctuary site in the face of ART where long-term 60 persistence of drug sensitive is possible, but rather a site where drug resistance is more 61 likely to evolve given gaps in adherence or other factors. Services, MDS). RevCEM-E7 cells were generated as previously described [10] . Macrophages and CD4+ PBMCs were generated as described above. CD4+ PBMCs ritonavir, nevirapine, abacavir, lamivudine, zidovudine, atazanavir and dolutegravir, 150 166 -5000 ng/ml for efavirenz, 90 -3000 ng/ml for tenofovir and 24 -780 ng/ml for 167 emtricitabine. RevCEM-E7 reporter cells grown at a concentration of 10 6 cells/ml in 4ml of growth 178 medium in 6-well plates (Corning) were infected with 2x10 7 RNA copies NL4-3 HIV per 179 ml. Cells were passaged in the presence of 3 concentrations of EFV, FTC, and TFV 180 using a dilution of 1:2 every 2 days, where half the cell culture was removed and fresh 181 medium with drugs was added.The three drug concentrations used were: 1) EFV tail, 182 18 ng/ml EFV; 2) CSF median, 51 ng/ml EFV, 190ng/ml FTC, 7 ng/ml TFV; and 3) 183 plasma median, 2200 ng/ml EFV, 194 ng/ml FTC and 66 ng/ml TFV. Proliferation of 184 uninfected cells was sufficient to maintain uninfected target cell numbers. The removed 185 fraction of cells was used to detect infection by flow cytometry using a timed acquisition 186 
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on a FACSCaliber machine. The concentration of infected cells was multiplied by the 187 volume and cumulative dilution factor to obtain the number of infected cells per well. For each sample, we used LC-MS/MS to assay for the presence of ART regimen 221 components. This consisted of the South African first line regimen of EFV, FTC, and 222 TFV as well as the protease inhibitors lapinovir and ritonavir (LPV/r) and the reverse 223 transcriptase inhibitor nevirapine (NVP). We excluded samples with LPV/r and NVP 224 so that only samples from individuals on first line therapy were analyzed further.
225
We modified an existing approach [46-48, 51, 74] to interrogate the cellular origin of 226 cell-free HIV by detecting host cell markers on the surface of the HIV virion, an 227 approach we term Host Marker on Virion detection (HMV, Fig 1A) . As the virus buds 228 out of the infected cell, it uses the cellular plasma membrane as its envelope [71] . The 229 cell membrane contains host surface markers which are retained by the virion on its 230 surface and can be bound with antibodies. We coupled the antibodies to magnetic 231 beads and used a VL assay to determine the number of bound virions after washing off 232 unbound virions (Fig 1A) . Using this technique, we successfully detected two cell 233 surface markers associated with cell type: CD26, a dipeptidyl-peptidase involved in T 234 cell activation and preferentially expressed by CD4+ T cells [29, 54] 
268
We used cell surface expression to confirm that T cells expressed a higher ratio of 269 CD26 to CD36 relative to MDMs. We detected CD26 and CD36 on the surface of
270
MDMs and CD3+ T cells from PBMCs (Fig 2A) . MDMs uniformly expressed CD36,
271
with little CD26 expression. In contrast, both CD26 and CD36 were expressed on CD3+ 272 T cells for CD3+ T cells (p < 0.0001, Fig 2B) . The T cell ratio of CD26 to CD36 Figure 3 . in vivo cellular source of HIV from participants with CSF Escape. 286 CSF samples from CSF Escape individuals were split into two, with half the sample 287 applied to a column with CD26 antibodies and the other to a column with CD36 antibodies 288 to obtain the ratio of virus bound by each. Median ratio of CSF Escape virus (left) was 289 compared to median ratios from in vitro derived virus from infected MDMs (middle) 290 or PBMCs (right) and was found to be significantly higher than the MDM ratio but 291 not different from the ratio of PBMC derived virus (p < 0.0001, p > 0.5 respectively, 292 Mann-Whitney non-parametric test).
293
We also compared the virus from viremic study participants, both from the CSF and 294 plasma, to that of participants with CSF escape (Fig 4) . We obtained no significant 295 differences between these groups, though interestingly the plasma ratios showed a and a second subset with virologic failure due to evolution of drug resistance (SFig 3). 316 Again consistent with previous studies, there was also a drop in FTC and TFV 317 concentrations in the CSF versus plasma, though this decrease was more attenuated for 318 FTC. Interestingly, in participants with CSF escape, there were no significant difference 319 between FTC concentrations in plasma versus CSF (SFig 3).
320
We compared drug concentrations between viremic, suppressed, and CSF Escape (Fig 5) . This indicates that there is a subset of viremic participants with low 324 adherence, and a sub-population of participants with low drug levels in the viremic 325 group can be clearly seen in the plasma compartment for all three drugs and in the CSF 326 compartment with FTC. However, there was no significant difference between CSF 327 levels of EFV, FTC, and TFV between the suppressed and CSF Escape groups (Fig 5) . 328 There was also no significant difference in plasma levels of all three drugs. This EFV concentration in the plasma was 7.8 ng/ml (IQR 2.7-1833 ng/ml) in viremic, 1080 336 ng/ml (IQR 538-2720 ng/ml) in suppressed, and 2250 ng/ml (IQR 1403-8048 ng/ml) 337 in CSF Escape. Median EFV concentration in the CSF was 2.9 ng/ml (IQR 1.9-3.6 338 ng/ml) for viremic, 31.1 ng/ml (IQR 25.2-96.3 ng/ml) for suppressed, and 50.7 (IQR 339 7.3-201 ng/ml) for CSF Escape. The concentrations in suppressed and CSF Escape were 340 significantly higher both in the plasma and CSF versus the viremic group (p = 0.0009 341 and p < 0.0001 respectively for plasma and p < 0.0001 and p = 0.0001 for CSF). 342 However, there was no significant difference between suppressed and CSF Escape EFV 343 concentrations in either the plasma of CSF (p = 0.26 and p > 0.99 respectively). B, FTC 344 concentrations in the plasma (left) and CSF (right) in viremic, suppressed, and CSF 345 Escape participants. Median FTC concentration in the plasma was 74.1 ng/ml (IQR 346 1.66-144 ng/ml) in viremic, 155 ng/ml (IQR 105-218 ng/ml) in suppressed, and 194 347 ng/ml, (IQR 139-337 ng/ml) in CSF Escape. Median FTC concentration in the CSF 348 was 10.1 ng/ml (IQR 1.0-124 ng/ml) for viremic, 98.3 ng/ml (IQR 60.6-153 ng/ml) for 349 suppressed, and 190 ng/ml (IQR 92.1-342 ng/ml) for CSF Escape. We asked whether the observed decrease in ART levels in the CSF in individuals with 370 CSF Escape were sufficient to enable the CSF act as a sanctuary site where drug 371 sensitive HIV can persist [50] . We therefore passaged drug sensitive HIV in vitro at the 372 measured CSF Escape median CSF and plasma concentrations of EFV, FTC, and TFV. 373 When passaging was done at the plasma median concentrations of EFV (2200 ng/ml), 374 FTC (194 ng/ml), and TFV (66 ng/ml), it led to a decline in infected cell numbers.
375
Infected cells were below the dilution corrected level of detection after 22 ± 3 days in 376 culture (Fig 6A) . The same experiment was performed at the CSF median drug levels of 377 EFV (51 ng/ml), FTC (190 ng/ml), and TFV (7 ng/ml). Similarly to plasma drug 378 concentrations, the number of infected cells declined until it was undetectable at 26 ± 3 379 days in culture (Fig 6B) . In agreement with the predicted effects of the drugs on viral 380 replication [62] , this indicates that ART levels in the CSF of CSF Escape individuals 381 are sufficient to result in a decay in infected cell numbers. 
390
We next calculated the estimated ART levels (Materials and Methods) after a 3 day 391 adherence gap. Interruptions on this timescale occur in approximately 20% of 392 individuals on ART monthly [32] . Due to the longer half-life of EFV relative to FTC 393 and TFV [2, 77] , such an interruption effectively leads to EFV monotherapy [73] . We 394 refer to this drug condition as "EFV tail". The EFV tail drug condition led to viral 395 replication and the evolution of the L100I EFV resistance mutant (Fig 6C-D, Fig 7) .
396
Transfer of cells infected with the evolved virus to the median plasma ART 397 concentration led to a decay in the number of infected cells (Fig 6C) . In contrast, 398 transfer to the median CSF ART concentrations led to an increase in infected cell 399 numbers (Fig 6D) and the evolution of FTC resistance and further resistance to EFV 400 (Fig 7) . Transfer of this virus to the plasma ART concentration led to an increase in 401 infected cell numbers (Fig 6D) and high level resistance. The mutations which arose at 402 these stages were the M184V or M184I FTC resistance mutations during median CSF 403 Escape ART levels, and the K103N high level EFV resistance mutation either at median 404 CSF Escape ART levels (2 experiments) or plasma median ART (1 experiment). In the 405 
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experiments where the K103N mutation arose early, it temporarily or permanently 406 supplanted the L100I mutation (Fig 7B-C) . Figure 6D . 411 L100I is a low level resistance mutation to EFV, M184V and M184I are high level 412 resistance mutations to FTC and K103N is a high level resistance mutation to EFV 413 according to the HIV Drug Resistance Database (https://hivdb.stanford.edu/).
414
These results predict that ART levels measured in the CSF of CSF Escape 415 individuals will lead to decay in infected cell numbers or, in the case of a gap in 416 adherence, the evolution of drug resistant HIV. This prediction is supported by several 417 studies showing drug resistance mutations in the face of ART in CSF from CSF Escape 418 and viremic individuals [69, 76] and our own limited sequencing (STable 1). Here, one of 419 the CSF Escape HIV sequences was drug sensitive. However, the CSF sample was 420 collected close to the ART start date, suggestive of a previously reported longer decay 421 time of drug sensitive HIV in the CSF compartment [24] . 422 
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Discussion
423
The presence of individuals with CNS Escape, where HIV is fully suppressed 424 peripherally but present in detectable levels in the CSF, suggests the possibility that, at 425 least in some individuals, the CNS can serve as a an HIV reservoir site either because of 426 HIV production from long lived tissue resident macrophages, or because of decreased
427
ART penetration leading to ongoing replication. Here, we tried to establish whether 428 macrophages were indeed the source of viremia in study participants with CSF Escape, 429 or whether drug levels in the CSF were low enough in CNS Escape for ART sensitive 430 HIV to replicate.
431
We used the ratio of the cell surface markers CD26 and CD36 to differentiate 
439
We confirmed the previously reported lower ART penetration into the CSF 440 compartment in our study population, which consisted of predominantly HIV Clade C 441 infected participants [37] . However, the drop in drug concentrations in the CSF relative 442 to the peripheral blood was similar between individuals with CSF Escape and those 443 who were fully suppressed in both compartments, ruling out lower ART concentrations 444 in the CSF as the reason for CSF Escape. While drug concentrations were lowered in 445 the CSF, they were sufficient to suppress replication by drug sensitive HIV in vitro.
446
Only an ART concentration where an adherence gap was assumed led to an increase in 447 infected cell numbers due to evolution of drug resistance in vitro. In this case, [17, 26, 42, 53, 70] , while a rare characterization of CD26 in these cells reports 459 them to be negative [21] . Second, we only tested the CSF, while HIV can persist in 460 additional CNS compartments [3] . This is a limitation of the current study. However, 461 virus which is strongly compartmentalized and unable to enter the CSF may have 462 difficulty exiting the CNS and seeding infection in the periphery on the two week 463 timescale which is usual for rebound of infection after ART interruption [15, 63] . Hence, 464 it may not be a reservoir which is the source of HIV rebound.
465
Based on the data presented here, we propose that the CSF may be a transient HIV RNA copies/ml from infected cells was loaded on columns to quantify CD26 and CD36. Shown are median and IQR for different blood donors. MDM values: CD26 median 208 HIV RNA copies/ml (IQR 85-440 copies/ml), CD36 median 5403 copies/ml (IQR 3076-9263 copies/ml). PBMC values: CD26 median 6600 copies/ml (IQR 5749-11185 copies/ml), CD36 median 5862 copies/ml (IQR 3309-5862 copies/ml). Median level of MDM CD26 is significantly lower from than MDM median CD36 (p < 0.05), PBMC median CD26 (p < 0.0001), and PBMC median CD36 (p < 0.001). Kruskal-Wallis non-parametric test with Dunn multiple comparisons correction. 
